The draft updated guidance on assessing and preventing falls in older people and people aged 50 and over at higher risk opens ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Belzutifan (Welireg, Merck Sharp & Dohme) is indicated for 'the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), ...

Belzutifan (Welireg) is available during the managed access period. It is a possible treatment for tumours associated with von Hippel-Lindau (VHL) disease in adults when localised procedures such as ...

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...

Next review: More evidence on belzutifan is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available to patients as part ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

when localised procedures are unsuitable or undesirable. It is only recommended if the conditions in the managed access agreement for belzutifan are followed. This recommendation is not intended to ...